Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities

Bibliography

• Lavanchy D. Evolving epidemiology of hepatitis C virus, Clin Microbiol Infect. 2011; 17(2):107-15
   Google Scholar
• Hepatitis C. World Health Organization. Fact sheet N°164 June 2011. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/index.html [Accessed January 2012]
   Google Scholar
• Smith RE. Hepatitis C virus therapies. Nat Rev Drug Discov 2006;5:715-16
   PubMed Web of Science ®Google Scholar
• Ciesek S, Manns MP. Hepatitis in 2010: the dawn of a new era in HCV therapy. 2011; 8(2):69-71
   Google Scholar
• Vezali E, Aghemo A, Colombo M. Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. Expert Opin Biol Ther 2011;11(3):301-13
   PubMed Web of Science ®Google Scholar
• Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part one: advances in basic knowledge for hepatitis C virus vaccine design. Expert Opin Ther Patents 2011;21(12):1811-30
   PubMed Web of Science ®Google Scholar
• Eisenstein M. Vaccines: a moving target. Nature 2011;8:474(7350):S16-17
   Google Scholar
• Tokyo Metropolitan Org Med Res and Toray Industries. Nucleic acid construct containing full-length genome of human Hepatitis C virus, recombinant full-length virus genome replicative cell having the nucleic acid construct transferred thereinto and method of constructing hepatitis C viral particles. WO2005080575; 2005
   Google Scholar
• Biomerieux SA, Inst Nat Sante Rech Med. Composition comprising specific non-structural proteins of hepatitis C virus, useful as prophylactic or therapeutic vaccines, also related expression vectors, microorganisms and antibodies. FR2855758; 2004
   Google Scholar
• Chiron Corp. Hepatitis C Virus Asialoglycoproteins. WO9533053; 1995
   Google Scholar
• Chiron Corp. Novel Hepatitis C E1 and E2 Truncated Polypeptides and Methods of obtaining the same. WO9604301; 1996
   Google Scholar
• Schijns V, Brewer MJ. New views on immunopotentiators in modern vaccines. Expert Rev Vaccines 2008;7(7):877-9
   Google Scholar
• Naarding MA, Falkowska E, Xiao H, Hepatitis C virus soluble E2 in combination with QuilA and CpG ODN induces neutralizing antibodies in mice. Vaccine 2011;29(16):2910-17
   Google Scholar
• Chiron Corp. Adjuvant formulation comprising a submicron oil droplet emulsion. WO9014837; 1990
   Google Scholar
• Amgen, Inc. and Univ Southern California. Recombinant Dna Derived Cholera Toxin Subunit Analogs. WO9219265; 1992
   Google Scholar
• Chiron Corp. Microparticles with adsorbent surfaces, methods of making same, and uses thereof. US6884435; 2005
   Google Scholar
• Smithkline Beecham Biolog. Hepatitis Vaccines Containing 3-O-Deacylated Monophoshoryl Lipid A. WO9319780; 1993
   Google Scholar
• Smithkline Beecham Biolog. Novel (Adjuvant) Compositions (For Vaccines). WO9857659; 1998 and WO200117550; 2001
   Google Scholar
• Smithkline Beecham Biolog. Oil in water vaccine compositions. WO9856414; 1998
   Google Scholar
• Smithkline Beecham Biolog. Vaccines. WO9517210; 1995
   Google Scholar
• Smithkline Beecham Biolog. Vaccines Against Hepatitis C. WO9701640; 1997
   Google Scholar
• Smithkline Beecham Biolog. Vaccine Compositions Containing 3-O Deacylated Monophosphoryl Lipid A. WO9421292; 1994
   Google Scholar
• Smithkline Beecham Biologicals. Oil in water emulsions containing saponins. WO199911241; 1999
   Google Scholar
• Papahadjopoulos DP, Szoka FC. Method of encapsulating biologically active materials in lipid vesicles. US4235871; 1980
   Google Scholar
• Liposome Technology, Inc. Liposomes with enhanced circulation time. US4837028; 1989
   Google Scholar
• Aventis Pasteur. Use of an amphipathic compound for providing an adjuvant to a subunit vaccine. US6472159; 2002
   Google Scholar
• Immunovaccine Technologies, Inc. Vaccines with enhanced immune response and methods for their preparation. US2002110568; 2002
   Google Scholar
• Chua BY, Eriksson EM, Brown LE, A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine 2008;26(37):4866-75
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Batens AH, Desombere I, Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. Hum Vaccin 2005;1(2):61-5
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Mazur W, Nevens F. Factors influencing progression of liver fibrosis in patients with chronic hepatitis C: results of the 3-year T2S-918-HCV study with HCVE1 therapeutic vaccine. J Hepatol 2008;48:S27-8
   Google Scholar
• Verstrepen BE, Depla E, Rollier CS, Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies. J Infect Dis 2011;204(8):37-44
   Google Scholar
• Chiron Corp. HCV E1E2 vaccine compositions. US2009258033; 2009
   Google Scholar
• Chiron Corp. NANBV diagnostics and vaccines. US6346375; 2002
   Google Scholar
• Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005;436:961-6
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier: NCT00500747. Available from: http://clinicaltrials.gov/ct2/show/results/NCT00500747 [Accessed on January 2012]
   Google Scholar
• Frey SE, Houghton M, Coates S, Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010;28(38):6367-73
   PubMed Web of Science ®Google Scholar
• Morein B. Matrix With Immunomodulating Activity. US5679354; 1997
   Google Scholar
• CSL Ltd. Immunogenic complexes and methods relating there to. WO200048630; 2000
   Google Scholar
• Takahashi HT, Takeshita B, Morein S, Induction of CD81 cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 1990;344:873
   PubMed Web of Science ®Google Scholar
• Wilson ADK, Lovgren-Bengtsson M, Villacres-Ericsson B, The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into ISCOMs primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines. Vaccine 1999;17:1282
   PubMed Web of Science ®Google Scholar
• Csl Ltd. Chelating Immunostimulating Complexes. WO9836772; 1998
   Google Scholar
• Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX. Vaccine 2009;27(33):4388-401
   PubMed Web of Science ®Google Scholar
• Csl Ltd. and Chiron Corp. Vaccine Compositions. US2010047271; 2010
   Google Scholar
• Pratten MK, Lloyd JB. Pinocytosis and phagocytosis: the effect of size of a particulate substrate on its mode of capture by rat peritoneal macrophages cultured in vitro. Biochim Biophys Acta 1986;881:307
   PubMed Web of Science ®Google Scholar
• Polakos N, Drane D, Cox J, Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J Immunol 2001;166:3589-98
   PubMed Web of Science ®Google Scholar
• Drane D, Maraskovsky E, Gibson R, Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine. A phase I study in healthy volunteers. Hum Vaccin 2009;5(3):151-7
   PubMed Web of Science ®Google Scholar
• United States Dept. of Health and Human Services, US. Chitosan enhancement of immune responses. WO2008039390; 2008
   Google Scholar
• Aparna Biosciences, USA. Therapeutic and vaccine polyelectrolyte nanoparticle compositions. WO2009079066; 2009
   Google Scholar
• Ct De Immunologia Molecular. Pharmaceutical Compositions Enhancing the Immunogenicity of Poorly Immunogenic Antigens. EA2003000064020011206; 2004
   Google Scholar
• Roohvand F, Aghasadeghi MR, Sadat SM, HCV core protein immunization with Montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses. Biochem Biophys Res Commun 2007;354(3):641-9
   PubMedGoogle Scholar
• Jin B, Wang RY, Qiu Q, Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA. Immunology 2007;122(1):15-27
   Google Scholar
• Qiu Q, Wang RY, Jiao X, Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants. Vaccine 2008;26(43):5527-34
   Google Scholar
• University of California. Immunostimulatory combinations of receptor agonists for vaccines and tumor immunotherapy. WO2007120368; 2007
   Google Scholar
• Coley Pharmaceuticals GmbH. Immunostimulatory P-class oligonucleotide formulations for use in treating diseases and as vaccine adjuvants. WO2007095316; 2007
   Google Scholar
• Yu H, Babiuk LA, van Drunen Littel-van den Hurk S, Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3. J Gen Virol 2004;85:1533-43
   PubMed Web of Science ®Google Scholar
• Changchun Huapu Biotechnology. CPG single-strand deoxynucleotides for use as adjuvant. WO2006056142; 2006
   Google Scholar
• Qiao M, Murata K, Retal DA. Hepatitis C virus like particles combined with novel adjuvant systems enhance virus-specific immune responses. Hepatology 2003;37(1):52-9
   PubMed Web of Science ®Google Scholar
• HS, M, Jeong Qiao Nascimbeni M,. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J Virol 2004;78(13):6995-7003
   Google Scholar
• Elmovalid GA, Qiao M, Jeong SH, Immunization with hepatitis C virus-like particles results in control of HCV infection in chimpanzees. Proc Natl Acad Sci USA 2007;104(20):8427-32
   Google Scholar
• Vajdy M, Selby M, Medina-Selby A, Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J Gen Virol 2006;87:2253-62
   PubMed Web of Science ®Google Scholar
• Han DK, Park K, Kim J-J. Thermosensitive pluronic Derivative Hydrogels With High Biodegradability And Biocompatibility For Tissue Regeneration and Preparation Method Thereof. US2010098762; 2010
   Google Scholar
• Wyeth Corp. Mycoplasma Hyopneumoniae Bacterin Vaccine. US2010062018; 2010
   Google Scholar
• Wolff JA, Malone RW, Williams P, Direct gene transfer into mouse muscle in vivo. Science 1990;247(4949 Pt 1):1465-8
   PubMed Web of Science ®Google Scholar
• Vical, Inc. and Wisconsin Alumni Res Found. Delivery of exogenous DNA sequences in a mammal. US5580859; 1996
   Google Scholar
• Vical, Inc. and Wisconsin Alumni Res Found. Induction of a protective immune response in a mammal by injecting a DNA sequence. US5589466; 1996
   Google Scholar
• Merck & Co, Inc. and Innogenetics NV. Polynucleotide tuberculosis vaccine. US5736524; 1998
   Google Scholar
• Univ California. Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides. US5679647; 1997
   Google Scholar
• Davis BS, Chang GJ, Cropp B, West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001;75(9):4040-7
   PubMed Web of Science ®Google Scholar
• Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo Electroporation. US2006084938; 2006
   Google Scholar
• Univ. Leland Stanford Junior. Intracellular delivery of nucleic acids using pressure. US5922687; 1999
   Google Scholar
• Du Pont. Method and Apparatus for Introducing Biological Substances Into Living Cells. US5204253; 1993
   Google Scholar
• Capone S, Zampaglione I, Vitelli A, Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J Immunol 2006;177(10):7462-71
   Google Scholar
• Univ. California. Methods and Compositions for In Vivo Gene Therapy. WO9324640; 1993
   Google Scholar
• Univ. Yale. Liposomal transfection of nucleic acids into animal cells. US5279833; 1994
   Google Scholar
• Molecular Express, Inc. Immunogenic Liposome compositions. EA004797; 2004
   Google Scholar
• Powderject Vaccines, Inc. Adjuvanted genetic vaccines. WO2001032208; 2001
   Google Scholar
• US Health. Surface Targeted Expression of A Modified Hepatitis C Virus Envelope Protein. WO9966033; 1999
   Google Scholar
• Forns X, Emerson SU, Tobin GJ, DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellular and on the cell surface. Vaccine 1999;17(15-16):1992-2002
   Google Scholar
• Univ Wuhan. The DNA vaccine of an anti-infection of hepatitis C virus. CN1943789; 2007
   Google Scholar
• Lagging LM, Meyer K, Hoft D, Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J Virol 1995;69(9):5859-63
   PubMed Web of Science ®Google Scholar
• Hartoonian C, Ebtekar M, Soleimanjahi H, Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine. Cytokine 2009;46(1):43-50
   PubMed Web of Science ®Google Scholar
• Cigb. Vaccine Composition Potentiated with DNA and Antigen Combination. RU2294212; 2007
   Google Scholar
• Alvarez-Lajonchere L, Shoukry NH, Gra B, Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a phase I clinical trial. J Viral Hepat 2009;16(3):156-67
   PubMed Web of Science ®Google Scholar
• Castellanos M, Cinza Z, Dorta Z, Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination. J Gene Med 2010;12(1):107-16
   PubMed Web of Science ®Google Scholar
• Tripep AB. Hepatitis C Virus Codon Optimized Non-Structural NS3/4A Fusion Gene. US2010104592; 2010
   Google Scholar
• Ahlen G, Nystrom J, Pult I, In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes. J Infect Dis 2005;192:2112-16
   PubMed Web of Science ®Google Scholar
• Ahlen G, Soderholm J, Tjelle T, In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression inflammation, and infiltration of CD3+ T cells. J Immunol 2007;179:4741-53
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier: NCT00563173. Available from. http://clinicaltrials.gov/show/NCT00563173 [Accessed on January 2012]
   Google Scholar
• Kast WM, Melief CJ. In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes. Immunol Lett 1991;30:229-32
   Google Scholar
• Buteau C, Markovic SN, Celis E. Challenges in the development of effective peptide vaccines for cancer. Mayo Clin Proc 2002;77:339–349.
   Google Scholar
• Toussaint NC, Maman Y, Kohlbacher O, Universal peptide vaccines - optimal peptide vaccine design based on viral sequence conservation. Vaccine 2011;29(47):8745-53
   PubMed Web of Science ®Google Scholar
• Rammensee H, Bachmann J, Emmerich NP, SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50(3-4):213-19
   PubMed Web of Science ®Google Scholar
• Merck & Co, Inc. System and method for automated selection of T-cell epitopes. WO2006124408; 2006
   Google Scholar
• Epimmune, Inc. HLA binding motifs and immunogenic peptides and their uses for vaccines against desired antigens. US20070055049; 2007
   Google Scholar
• Henry M. Jackson Foundation for the Advancement of Military Medicine Institute. Targeted identification of immunogenic peptides. WO2009112792; 2009
   Google Scholar
• Epimmune, Inc. Hla Binding Peptides and Their Uses. WO0220035; 2002
   Google Scholar
• Algonomics NV. Method, Computing Routine, Device for Predicting Properties of MHC/PEPTIDE Complexes, and Data and Peptides Produced Therefrom. WO03105058; 2003
   Google Scholar
• Imp College Innovations Ltd. Identification of HLA-DR Restricted HCV Epitopes. WO0234770; 2002
   Google Scholar
• Epimmune, Inc. Inducing cellular immune responses to Hepatitis C virus using peptide and nucleic acid compositions. WO0121189; 2001
   Google Scholar
• Scripps Research Inst. Peptides for Inducing Cytotoxic T Lymphocyte Responses to Hepatitis C Virus. WO9525122; 1995
   Google Scholar
• Innogenetics NV. Immunodominant Human T-Cell Epitopes of Hepatitis C Virus. WO9512677; 1995 and JP2004194668; 2004
   Google Scholar
• Cytel Corp. HLA-A2.1 and HLA Binding Peptides and Their Uses. WO9420127; 1994 and WO9403205; 1994
   Google Scholar
• Pharmexa, Inc. Inducing Cellular Immune Responses to Hepatitis B Virus Using Peptide and Nucleic Acid Compositions. US2010068228; 2010
   Google Scholar
• Epimmune, Inc. Compositions and methods for eliciting CTL immunity. US6419931; 2002
   Google Scholar
• Cytel Corp. Alteration of immune response using pan DR-binding peptides. US5736142; 1998
   Google Scholar
• Immuosystems Gmbh. Epitopes of Virus Hepatitis C Specifically CD4+ T Lymphocytes. WO0226785; 2002
   Google Scholar
• Innogenetics N.V. and IDM Pharma, Inc. Peptides for inducing a CTL and/or HTL responses to Hepatitis C virus. WO2005118626A2; 2005
   Google Scholar
• US Health. Hepatitis C Virus Core Peptide for Stimulation of Cytotoxic T Lymphocytes and Diagnosis of HCV Exposure. WO9527733; 1995
   Google Scholar
• Wedemeyer H, Berg T, Manns MP, Induction of the TH1/TC1 type immunity in chronic hepatitis C non-responder patients with the therapeutic peptide vaccine IC41. J Hepatol 2005;42(Suppl 2):A19
   Google Scholar
• Frisch J, Tauber E, Buerger V, HCV Vaccines for Chronic HCV Patients. US2010322972; 2010
   Google Scholar
• Firbas C, Jilma B, Tauber E, Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006;24:4343-53
   PubMed Web of Science ®Google Scholar
• Klade CS, Wedemeyer H, Berg T, Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroent 2008;134:1385-95
   Google Scholar
• Buschle M, Frisch J, Klade C, HCV vaccines. US2009130135; 2009
   Google Scholar
• Wedemeyer H, Schuller E, Schlaphoff V, Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine 2009;27(37):5142-515
   PubMed Web of Science ®Google Scholar
• Firbas C, Boehm T, Buerger V, et al. Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. Vaccine 2010;28(12):2397-407
   PubMed Web of Science ®Google Scholar
• Yutani S, Yamada A, Yoshida K, et al. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine 2007;25(42):7429-35
   PubMed Web of Science ®Google Scholar
• Green Peptide Co. Ltd. Peptide Derived from Hepatitis C Virus. US2010292138; 2010
   Google Scholar
• Yutani S, Komatsu N, Shichijo S, et al. Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles. Cancer Sci 2009;100(10):1935-42
   PubMed Web of Science ®Google Scholar
• Fytili P, Dalekos GN, Schlaphoff V, Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. Vaccine 2008;26:3818-26
   PubMedGoogle Scholar
• Intercell AG. Method for Isolating Hepatitis C Virus Peptide. US2009081246; 2009 and JP2010265262; 2010
   Google Scholar
• Gowans EJ, Roberts S, Jones K, A Phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol 2010;53(4):599-607
   Google Scholar
• Moser C, Amacker M, Kammer AR, Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev Vaccin 2007;6(5):711-21
   PubMed Web of Science ®Google Scholar
• Pevion Biotech AG. Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof. EP2014279; 2009
   Google Scholar
• ClinicalTrials.gov Identifier: NCT00445419. Available from: http://clinicaltrials.gov/show/NCT00445419 [Accessed on January 2012]
   Google Scholar
• Memarnejadian A, Roohvand F, Arashkia A, Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice. Protein Pept Lett 2009;16(7):842-50
   PubMedGoogle Scholar
• Arashkia A, Roohvand F, Memarnejadian A, Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice. Virus Genes 2010;40(1):44-52
   PubMedGoogle Scholar
• Im EJ, Hong JP, Roshorm Y, Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges. PLoS Pathog 2011;7(5):e1002041
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ma CJ, Ni L, Cross-talk between programmed death-1 and suppressor of cytokine signaling-1 in inhibition of IL-12 production by monocytes/macrophages in hepatitis C virus infection. J Immunol 2011;186(5):3093-103
   PubMedGoogle Scholar
• Memarnejadian A, Roohvand F. Fusion of HBsAg and prime/boosting augment Th1 and CTL responses to HCV polytope DNA vaccine. Cell Immunol 2010;261(2):93-8
   Google Scholar
• Martin P, Simon B, Lone YC, A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus. Vaccine 2008;26(20):2471-81
   Google Scholar
• Chiron Corp. Multiple Epitope Fusion Protein. WO9744469; 1997
   Google Scholar
• Chiron Corp. Hepatitis C virus multi copy epitope fusion antigens. US6428792; 2002
   Google Scholar
• First Hospital of Jilin Univer. Multi-epitope gene of hepatitis C and its nucleic acid vaccine. CN1690207; 2005
   Google Scholar
• Nationwide Childrens Hospital. AVV Vectors and Methods. US2010260800; 2010
   Google Scholar
• Univ Massachusetts. Novel AAV 'S and Uses Thereof. WO2010138263; 2010
   Google Scholar
• Targeted Genetics Corp. and Childrens Hospital, Inc. Recombinant AAV Based Vaccine Methods. WO2006073496; 2006
   Google Scholar
• Shiver JW, Fu TM, Chen L, Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-5
   PubMed Web of Science ®Google Scholar
• Casimiro DR, Chen L, Fu TM, Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003;77:6305-13
   PubMed Web of Science ®Google Scholar
• D'Ambrosio E, Del Grosso N, Chicca A, Neutralizing antibodies against 33 human adenoviruses in normal children in Rome. J Hyg 1982;89:155-61
   PubMedGoogle Scholar
• Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA, Italy. Chimpanzee adenovirus vaccine carriers. WO2005071093; 2005
   Google Scholar
• The Trustees of the University of Pennsylvania, USA. Sequences for simian adenoviruses of subfamily C, SAdV-40, SAdV-31 or SAdV-34, and uses thereof for gene delivery, vaccination and recombinant production. WO2009105084; 2009
   Google Scholar
• Kaslow David C, Bett Andrew J. Hepatitis C virus Vaccine. US2010129901; 2010
   Google Scholar
• Capone S, Meola A, Ercole BB, A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that Overcomes preexisting anti-Ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J Virol 2006;80(4):1688-99
   PubMedGoogle Scholar
• Fattori E, Zampaglione I, Arcuri M, Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes. Gene Ther 2006;13:1088-96
   PubMed Web of Science ®Google Scholar
• Okairos. AG Switzerland. Simian Adenovirus Nucleic Acid- and Amino Acid-Sequences, Vectors Containing same, and Uses Thereof. WO2010086189; 2010
   Google Scholar
• Folgori A, Capone S, Ruggeri L, A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006;12:190-7
   PubMed Web of Science ®Google Scholar
• Colloca S, Folgori A, Lahm A. Hepatitis C Virus Nucleic Acid Vaccine. US2009035277; 2009
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01070407. Available from: http://clinicaltrials.gov/ct2/show/NCT01070407 [Accessed on January 2012]
   Google Scholar
• Mikkelsen M, Holst PJ, Bukh J, Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain. J Immunol 2011;186(4):2355-64
   Google Scholar
• Peking University Peoples Hospital. Anti-HCV Vaccine and Preparation Methods and Uses Thereof. US2010310605; 2010
   Google Scholar
• Li W, Krishnadas DK, Li J, Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immunotherapy. J Immunol 2006;176(10):6065-75
   Google Scholar
• Mayr A, Stickl H, Muller HK, The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl Bakteriol 1978;167(5–6):375-90
   Google Scholar
• Sutter G, Moss B. Non-replicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992;89(22):10847-51
   PubMed Web of Science ®Google Scholar
• Diamond Don and Wang Zhongde. Genetically Stable Recombinant Modified Vaccinia Ankara (RMVA) Vaccines and Methods of Preparation Thereof. US2010316667; 2010
   Google Scholar
• Internat Aids Vaccine Initiati. Recombinant Modified Ankara Viral HIV-I Vaccine. WO2008118936; 2008
   Google Scholar
• Delcayre A, Laus R, Mandl S. Methods for treating cancer with MVA. US2011008294; 2011
   Google Scholar
• Sutter G, Bujard H, Westerfeld N, Recombinan MVA strains as potential vaccines against p. falciparum Malaria. US2006127413; 2006
   Google Scholar
• Chaplin P. Recombinant Modified Vaccinia Virus Measles Vaccine. US2011052627; 2011
   Google Scholar
• Abraham JD, Himoudi N, Kien F, Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins. Vaccine 2004;22(29–30):3917-28
   Google Scholar
• Rollier CS, Paranhos-Baccala G, Verschoor EJ, Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 2007;45:602-13
   PubMed Web of Science ®Google Scholar
• Transgene SA. Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use. US2007269460; 2007
   Google Scholar
• Fournillier A, Gerossier E, Evlashev A, An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine 2007;25:7339-53
   PubMedGoogle Scholar
• ClinicalTrials.gov Identifier: NCT00529321. Available from: http://clinicaltrials.gov/ct2/show/NCT00529321 [Accessed on January 2012]
   Google Scholar
• Li G. Recombinant Alphavirus vectors and methods of using same. US2008096274; 2008
   Google Scholar
• Chul Joong K. Preparation of Infectious HCV-Like Particles. KR20030013585. 2003
   Google Scholar
• Lin Y, Kwon T, Polo J, Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J Virol 2008;82(15):7492-503
   PubMedGoogle Scholar
• Zubkova I, Choi YH, Chang E, T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation. Vaccine 2009;27(19):2594-602
   PubMedGoogle Scholar
• Stubbs AC, Martin KS, Coeshott C, Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 2001;7(5):625-9
   PubMed Web of Science ®Google Scholar
• GlobeImmune, Inc. Yeast-based vaccine for inducing an immune response. WO2007092792; 2007
   Google Scholar
• GlobeImmune, Inc. Yeast-Based Therapeutic for Chronic Hepatitis C Infection. US2010150963; 2010
   Google Scholar
• Haller AA, Lauer GM, King TH, Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine 2007;25:1452-63
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier: NCT00124215. Available from: http://clinicaltrials.gov/ct2/show/NCT00124215 and yeast pages of globeimmune: http://www.homeyeastinfectionremedy.org/yeast-infection-treatment/globeimmune-expands-gi-5005-02-phase-2b-trial-to-include-additional-treatment-naive-il28b-tt-subjects-with-chronic-genotype-1-hcv/ [Accessed on January 2012]
   Google Scholar
• Mishra N, Goyal AK, Tiwari S, Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers. Expert Opin Ther Patents 2010;20(5):661-79
   PubMed Web of Science ®Google Scholar
• Powderject Vaccines, Inc. Powder compositions. WO2001093829; 2001
   Google Scholar
• Tripep AB. Transdermal Formulations Containing Hepatitis C Virus Immunogens. WO2008004992; 2008
   Google Scholar
• Wedemeyer H, Gagneten S, Davis A, Oral immunization with HCV-NS3-transformed salmonella: induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology 2001;121(5):1158-66
   Google Scholar
• Cao J, Chen Z, Ren Y, Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice. Vaccine 2011;29(20):3714-23
   Google Scholar
• Peters J, Stoger E. Transgenic crops for the production of recombinant vaccines and anti-microbial antibodies. Hum Vaccin 2011;7(3):367-74
   PubMed Web of Science ®Google Scholar
• Nemchinov LG, Liang TJ, Rifaat MM, Development of a plant-derived subunit vaccine candidate against hepatitis C virus. Arch Virol 2000;145(12):2557-73
   PubMed Web of Science ®Google Scholar
• Nuzzaci M, Vitti A, Condelli V, In vitro stability of Cucumber mosaic virus nanoparticles carrying a Hepatitis C virus-derived epitope under simulated gastrointestinal conditions and in vivo efficacy of an edible vaccine. J Virol Methods 2010;165(2):211-15
   PubMed Web of Science ®Google Scholar
• Qingdao Science Technology Uni. HCV composite multi-epitope transgene plan oral vaccine. CN101070544; 2007
   Google Scholar
• Keating GM, Noble S. Recombinant hepatitis B (Engerix-B) vaccine: a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003;63:1021-51
   PubMed Web of Science ®Google Scholar
• Patient R, Hourioux C, Vaudin P, Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies. New Biotechnol 2009;25(4):226-34
   PubMed Web of Science ®Google Scholar
• Chiron Corp. HBV/HCV virus-like particle. US6740323; 2004. and EP1535628; 2005
   Google Scholar
• Univ Wuhan (CN). Yeast strain for preparing PreS-E1-E2 vaccine of hepatitis B and hepatitis C virus and preparation method thereof. CN1908157; 2007
   Google Scholar
• Univ Francois Rabelais de Tour (FR). Novel fusion proteins and use thereof for preparing Hepatitis C Vaccines. WO2009153518; 2009
   Google Scholar
• Wu CL, Leu TS, Chang TT, Hepatitis C virus core protein fused to hepatitis B virus core antigen for serological diagnosis of both hepatitis C and hepatitis B infections by ELISA. J Med Virol 1999;57:104-10
   PubMedGoogle Scholar
• Claeys H, Volckaerts A, Mertens W, Localization and reactivity of an immunodominant domain in the NS3 region of hepatitis C virus. J Med Virol 1995;45:273-81
   Google Scholar
• Mihailova M, Boos M, Petrovskis I, Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus. Vaccine 2006;24:4369-77
   PubMed Web of Science ®Google Scholar
• Univ First Hospital Jilin. Chimeric antigen gene of hepatitis B and hepatitis C and its nucleic acid vaccine. CN1690206; 2005
   Google Scholar
• Tripep AB. Immunogen Platform. US2009214593; 2009
   Google Scholar